ASP Isotopes (ASPI) Projected to Post Quarterly Earnings on Monday

ASP Isotopes (NASDAQ:ASPI) is anticipated to announce its Q4 2025 resultson Monday, March 30th. Analysts expect the company to announce earnings of ($0.1367) per share and revenue of $2.0310 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

ASP Isotopes Price Performance

ASPI stock opened at $4.22 on Monday. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04. The firm has a market cap of $467.74 million, a price-to-earnings ratio of -3.25 and a beta of 3.55. The company’s fifty day simple moving average is $6.05 and its 200 day simple moving average is $7.38. ASP Isotopes has a 12-month low of $3.92 and a 12-month high of $14.49.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Cantor Fitzgerald began coverage on ASP Isotopes in a research report on Thursday, December 4th. They issued an “overweight” rating and a $13.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research note on Monday, December 29th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a report on Monday, November 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and a consensus target price of $13.00.

Insider Activity

In other news, COO Robert Ainscow sold 8,438 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $5.44, for a total transaction of $45,902.72. Following the transaction, the chief operating officer owned 1,537,817 shares of the company’s stock, valued at $8,365,724.48. This represents a 0.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ASPI. Quantbot Technologies LP acquired a new stake in ASP Isotopes in the third quarter valued at approximately $34,000. BNP Paribas Financial Markets lifted its holdings in shares of ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after purchasing an additional 2,548 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of ASP Isotopes by 30.4% in the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock worth $81,000 after purchasing an additional 1,953 shares in the last quarter. Tower Research Capital LLC TRC grew its position in ASP Isotopes by 96.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock valued at $80,000 after purchasing an additional 5,353 shares during the period. Finally, Guggenheim Capital LLC acquired a new stake in ASP Isotopes in the 4th quarter valued at $72,000. 16.80% of the stock is owned by institutional investors and hedge funds.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.